Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act
Detailed guidance document from FDA and regulatory agencies.
Document Details
Guidance Document
February 6, 2024
February 5, 2024
4bb3edae-dd26-480a-a41b-2f2b6bd19311
Related Documents
Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products Questions and Answers
Guidance DocumentJuly 23, 2024Center for Drug Evaluation and Research
Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products
Guidance DocumentMarch 21, 2024Center for Drug Evaluation and Research
Biomarker Qualification: Evidentiary Framework: Draft Guidance for Industry and FDA Staff
Guidance DocumentDecember 12, 2018Center for Drug Evaluation and Research
Quick Actions
Transform Regulatory Data into Actionable Intelligence
Join leading pharmaceutical and medical device companies who trust KeyPedia for their regulatory compliance needs.